Genediva, one of the largest IVF enterprises in China, through continuous independent R & D, product cooperation and license, has built a product portfolio covering the entire life cycle of IVF, including drugs, IVF laboratory information systems, equipment, and various consumables.
Genediva originates from GenSci Pharmaceutical's Women's Health BU. Genediva, a wholly-owned subsidiary established by GenSci Pharmaceutical in 2023, focuses on women's health businesses. It operates with two core business units: assisted reproduction and women's health. The company aims to create a diversified product portfolio covering the entire lifecycle of women, with a comprehensive layout encompassing full-stack solutions for infertility, as well as gynecology-related areas such as menopause, gynecological infections, gynecological devices, gynecological tumors, pelvic floor health, and gynecological consumer products. It offers a women's health product matrix that combines "serious medical care and consumer healthcare" approaches.
Company Details
- Employees
- 2
- Address
- Xuhui District, 上海,china
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Keywords
- Dubai.
- HQ
- 上海
Genediva Questions
Genediva's LinkedIn profile is https://cn.linkedin.com/company/genediva
Genediva has
2 employees.
View email and phone details for 2
employees at Genediva.
Genediva's industry is
Pharmaceutical Manufacturing
Genediva's top competitors are
Optima Lela,inc,
Stryker,
株式会社 Optima Lela,
上海荣泰健康科技股份有限公司,
Rotai Health,
Malaysian Genomics Resource Centre Berhad.
Genediva's categories are Pharmaceutical Manufacturing
